Is Plus Therapeutics, Inc. overvalued or undervalued?

As of 14 August 2023, the valuation grade for Plus Therapeutics, Inc. has moved from does not qualify to risky, indicating a significant shift in its perceived financial health. The company appears to be overvalued given its current metrics, particularly with a price-to-book value of -0.45 and an EV to EBITDA ratio of -0.06, both suggesting negative valuations. Furthermore, the P/E ratio remains not applicable as the company is loss-making, which adds to the concerns regarding its financial stability.
In comparison to its peers, Plus Therapeutics, Inc. is underperforming, as seen with ABVC BioPharma, Inc. having a P/E ratio of -15.31 and Tempest Therapeutics, Inc. at -0.63, both of which are also categorized as not qualifying. The stark contrast in performance is highlighted by Plus Therapeutics' year-to-date return of -83.97%, significantly lagging behind the S&P 500's 2.44% return. Overall, the combination of negative ratios and poor stock performance suggests that Plus Therapeutics is overvalued in the current market context.